AbbVie Inc.
ABBV Healthcare Drug Manufacturers General
AbbVie Inc.’s revenue for fiscal 2025 (year ended December 2025) was $61.2 billion, up 8.57% from fiscal 2024. In the quarter to June 2026, revenue grew 10.2%, EPS grew 290.4%, free cash flow fell 36.2% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years.
Follow ABBV
AbbVie Inc. (ABBV) Return on assets
AbbVie Inc.'s return on assets over the twelve months to 30 June 2026 was 4.61%, up 1.5 percentage points from fiscal 2025 (3.11%). Over the past ten years it has ranged from 3.11% (fiscal 2025) to 12.8% (fiscal 2015) — the current reading is the lowest in ten years. That is above the Drug Manufacturers General industry median of 2.57% and above the Healthcare sector median of −30.9%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 3.11% | (0.03) |
| FY2024 | 3.14% | (0.38) |
| FY2023 | 3.52% | (4.74) |
| FY2022 | 8.26% | 0.49 |
| FY2021 | 7.77% | 3.92 |
| FY2020 | 3.85% | (6.77) |
| FY2019 | 10.6% | 1.88 |
| FY2018 | 8.74% | 0.98 |
| FY2017 | 7.76% | (2.23) |
| FY2016 | 9.99% | (2.78) |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| LLY Eli Lilly and Company compare | 22.0% |
| NVS Novartis AG compare | 11.3% |
| AMGN Amgen Inc. compare | 9.53% |
| AZN AstraZeneca PLC compare | 9.15% |
| ABBV AbbVie Inc. | 4.61% |
| MRK Merck & Co., Inc. compare | 2.57% |
| PFE Pfizer Inc. compare | 2.13% |
| JNJ Johnson & Johnson compare | 0.00% |
| GILD Gilead Sciences, Inc. compare | −6.17% |
| Drug Manufacturers General industry median | 2.57% |
| Healthcare sector median | −30.9% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on ABBV
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement